Skip to main content
PepStack
Wiki · Profile

Gonadorelin

GnRH · Gonadotropin-Releasing Hormone · Factrel

Hormonal AxisApproved
From$5.40/mgCompare prices
MW
1182.3g/mol
Formula
C55H75N17O13

Gonadorelin is a decapeptide classified as a gonadotropin-releasing hormone (GnRH), originating from the hypothalamus, where it plays a crucial role in regulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Researchers primarily study gonadorelin for its potential applications in reproductive health and its implications in various therapeutic contexts, including hormonal regulation and cancer treatment. Key findings indicate that gonadorelin can significantly inhibit tumor growth in models of colorectal cancer and enhance reproductive performance in livestock by inducing ovulation and synchronizing estrus. Additionally, studies suggest that innovative formulations of gonadorelin, such as those using nanoparticles, may improve its efficacy and reduce required dosages without compromising reproductive outcomes. Current research continues to explore the diverse applications of gonadorelin, particularly in the fields of oncology and reproductive biotechnology.

Chemical Profile

Chemical Profile

Chemical structure
Chemical Structure
FormulaC55H75N17O13
Molecular Weight1182.3 g/mol
CAS Number33515-09-2
PubChem CID638793

Half-Life

SCSubcutaneous

Data limited

IMIntramuscular

Data limited

IVIntravenous

~2 to 4 minutes

INIntranasal

Data limited

POOral

Poor bioavailability

Gonadorelin is rapidly metabolized and cleared from the circulation, necessitating specific routes of administration for sustained effects.

Mechanism

Mechanism of Action

Gonadorelin acts primarily by binding to the gonadotropin-releasing hormone receptor (GnRHR) on the anterior pituitary gland, activating the phospholipase C (PLC) signaling pathway, which leads to increased intracellular calcium levels and subsequent secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This release of gonadotropins regulates reproductive processes such as ovulation and steroidogenesis. While the basic mechanism is understood, the full complexity of downstream signaling pathways and their interactions in various tissues remains to be fully elucidated.

Research

76 Research Publications

1,315

Total Citations

18

Human/RCT

2.2

Avg. Influence

2023

Latest

Sort
Filter
#01

Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs.

In VitroInfluence10.0
221
The study demonstrated that the stability of various peptides, including gonadorelin, in human gastrointestinal fluids varies significantly, influencing their potential for oral delivery.
150 ng/mousesubcutaneously(mouse)125 μgintramuscular(goat)50 μg/mLintramuscular(goat)200 μg
PubMed
#02

Preparation and characterization of solid lipid nanoparticles containing peptide.

In VitroInfluence8.0
165
The study demonstrated that gonadorelin-loaded solid lipid nanoparticles exhibited a slow release profile, indicating potential for prolonged delivery of hydrophilic peptide drugs.
150 ng/mousesubcutaneously(mouse)200 μg125 μgintramuscular(goat)50 μg/dogsubcutaneously(dog)50 μgintramuscular(cat)100 µg200 μg
PubMed
#03

Hypothalamic mechanisms of obesity-associated disturbance of hypothalamic-pituitary-ovarian axis.

Chen Xiaolin, et al. · Trends in endocrinology and metabolism: TEM · 2022

ReviewInfluence1.0
61
Researchers reviewed how obesity affects the hormonal regulation of ovulation in women. They found that the hypothalamus, which plays a crucial role in ovulation, is influenced by metabolic signals and inflammation, leading to ovulatory disorders commonly seen in obese women. The study highlights the need for further research to develop new treatments for these hormonal imbalances.

Key findings

  1. 01Researchers observed that ovulatory disorders are prevalent among obese women due to disruptions in the hypothalamic-pituitary-ovarian axis.
  2. 02The hypothalamus receives metabolic signals that regulate the release of gonadotropin-releasing hormone (GnRH), essential for ovulation.
  3. 03Inflammation in the hypothalamus can also impact ovulation independently of obesity.
PubMed
#04

The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer.

Emons Günter & Gründker Carsten · Cells · 2021

ReviewInfluence1.0
51
Researchers reviewed the role of Gonadotropin-Releasing Hormone (GnRH) in endometrial cancer, a common type of cancer in women. They found that many endometrial cancer cells express GnRH and its receptor, which may influence cell growth and death. The study also highlighted that certain GnRH-based treatments showed promise in early-stage cancer but had limited effectiveness in advanced cases.

Key findings

  1. 01Researchers observed that most endometrial cancer cells express GnRH and its receptor, suggesting a role in regulating cancer cell behavior.
  2. 02The study found that GnRH agonists can inhibit cancer cell growth and induce cell death in laboratory models.
  3. 03Researchers noted that while some GnRH treatments showed potential in early-stage endometrial cancer, they were less effective in advanced or recurrent cases.
PubMed
#05

Gonadotropin-releasing hormone antagonists.

Herbst Karen L · Current opinion in pharmacology · 2003

ReviewInfluence1.0
51
Researchers observed that gonadotropin-releasing hormone (GnRH) antagonists can block the hormone's action, which may lead to new treatments for various hormone-related conditions. These compounds are currently being tested for use in assisted reproduction and could potentially be used for male contraception and to inhibit certain cancers. The study highlights the expanding role of GnRH antagonists in medicine.

Key findings

  1. 01GnRH antagonists inhibit the hormone from binding to its receptor, effectively reducing hormone activity.
  2. 02These compounds are in clinical trials for assisted reproduction and may soon be available for broader applications.
  3. 03Potential future uses include hormonal male contraception and targeting specific cancer cells.
PubMed
#06

Stability of peptide drugs in the colon.

In VitroInfluence1.0
49
The study demonstrated that gonadorelin and other small peptides exhibit varying degradation rates in a colonic model, with stability linked to peptide lipophilicity.
150 ng/mousesubcutaneously(mouse)200 μg125 μgintramuscular(goat)50 μg/dogsubcutaneously(dog)50 μgintramuscular(cat)100 µg200 μg
PubMed
#07

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

ReviewInfluence3.0
46
The review indicated that goserelin, a gonadorelin analogue, is effective in managing hormone-dependent conditions and shows comparable efficacy to surgical options in certain cancers.
150 ng/mousesubcutaneously(mouse)200 μg125 μgintramuscular(goat)50 μg/dogsubcutaneously(dog)50 μgintramuscular(cat)100 µg200 μg
PubMed
#08

Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle.

AnimalInfluence1.0
46
The study demonstrated that gonadorelin treatment resulted in a significantly lower LH release compared to lecirelin and buserelin in cattle, indicating differences in their biological responses.
150 ng/mousesubcutaneously(mouse)200 μg125 μgintramuscular(goat)50 μg/dogsubcutaneously(dog)50 μgintramuscular(cat)100 µg200 μg
PubMed
#09

The effects of 3 gonadorelin products on luteinizing hormone release, ovulation, and follicular wave emergence in cattle.

AnimalInfluence6.0
43
Researchers observed that the gonadorelin formulation C induced a greater LH release and higher ovulatory rates in Holstein cows compared to other formulations.
150 ng/mousesubcutaneously(mouse)200 μg125 μgintramuscular(goat)50 μg/dogsubcutaneously(dog)50 μgintramuscular(cat)100 µg200 μg
PubMed
#10

Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Review
38
The review highlighted that buserelin, a GnRH agonist, exhibits comparable efficacy to orchidectomy in treating hormone-sensitive prostate cancer while presenting a lower incidence of adverse effects.
150 ng/mousesubcutaneously(mouse)200 μg125 μgintramuscular(goat)50 μg/dogsubcutaneously(dog)50 μgintramuscular(cat)100 µg200 μg
PubMed
Safety

Safety & Handling

Research Gaps

No comprehensive human clinical trials have been conducted to evaluate the long-term effects and safety of gonadorelin in various therapeutic contexts, particularly concerning its use in cancer treatment and reproductive health. Additionally, the precise mechanisms by which gonadorelin modulates immune responses and influences tumorigenesis remain poorly understood, necessitating further investigation.

Solubility

Gonadorelin is soluble in water and aqueous buffers but has limited solubility in organic solvents like acetonitrile and DMSO.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Approved by the FDA for specific diagnostic and therapeutic uses. Not a controlled substance.

🇦🇺AU

Listed in the Australian Register of Therapeutic Goods for specific uses. Not a controlled substance.

🇬🇧UK

Approved by the MHRA for specific medical uses. Not a controlled substance.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Community Insights

Publications per Year

47 total
1
78
1
83
1
88
3
90
2
91
2
96
1
99
2
03
1
04
1
06
1
13
1
14
4
15
2
17
2
18
2
19
2
20
1
21
5
22
8
23
3
24
1
25
Pricing

Price Comparison

  • BESTRCpeptidesEU
    10mg
    $54.00
    Price/mg
    $5.40/mg
    View
  • Modern ResearchUS
    5mg
    $34.99
    Price/mg
    $7.00/mg
    View
  • Research Peptides UKUK
    2mg
    $50.80
    Price/mg
    $25.40/mg
    View
  • PeptaNovaEU
    0.5mg
    $48.60
    Price/mg
    $97.20/mg
    View
  • Progen PeptidesUS
    0.1mg
    $32.99
    Price/mg
    $329.90/mg
    View

Top 5 of 17 offers from 15 vendors. Prices updated daily.

See all Gonadorelin prices
Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for Gonadorelin

Serum Level Visualizer

Visualize Gonadorelin serum levels over time

Mechanism

Related Peptides

OxytocinHCGEnclomipheneLeuprolideKisspeptin-10

Track Gonadorelin in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp StoreGet it onGoogle Play
Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer